ILXQuant Mental Health and Psychedelic Medicine Basket Index
Fixed-basket index of 10 companies at the frontier of the mental health treatment revolution -- pure-play psychedelic developers (COMPASS Pathways, atai Life Sciences, MindMed), approved CNS innovators (Axsome, Acadia, Intra-Cellular), neuroactive steroids (Sage), and established neuroscience platforms (Jazz, Alkermes, Biogen). The FDA Breakthrough Therapy designations for psilocybin-assisted therapy represent the largest paradigm shift in psychiatry since the introduction of SSRIs. Rebalances quarterly to equal weight.
- Index identifier
- ILXMND
- Category
- Basket
- Universe
- Fixed basket -- 10 mental health and psychedelic medicine companies (equal weight)
- Currency
- USD
- Inception
- 2021-09-07
- Rebalancing
- Quarterly (first Monday of March, June, September, December)
- Index fee
- 0.60% p.a.
- Reference benchmark
- Health Care SPDR (XLV)
Performance and risk
All figures below are measured over a trailing window of up to 1,260 trading days (approximately five years), not since index inception.
| Annualised return | +9.28% |
|---|---|
| Sharpe ratio | 0.28 |
| Calmar ratio | 0.24 |
| Volatility | 33.19% |
| Maximum drawdown | -38.20% |
| Return, 1 month | — |
| Return, 3 months | — |
| Return, 1 year | — |
| Return, year to date | +11.49% |
Full performance history, drawdown analysis, rolling risk metrics and portfolio breakdowns for this index are available in the ILX Quant platform.